
1 to 2 hours:
time to peak plasma concentrations (Tmax)1
11 hours:
elimination half-life1
The clinical significance of these data is not known.
see qulipta
dosing options
1 to 2 hours:
time to peak plasma concentrations (Tmax)1
11 hours:
elimination half-life1
The clinical significance of these data is not known.
see qulipta
dosing options
QULIPTA® (atogepant) is indicated for the preventive treatment of migraine in adults.
QULIPTA® (atogepant) is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
Dose modifications are recommended when using the following:
In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.
Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.
Avoid use in patients with severe hepatic impairment.
US-QLP-230210
The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.
Please see full Prescribing Information.
Please see full Prescribing Information.